The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Poly(ethylene glycol) (PEG) is widely used as a gold standard in bioconjugation and nanomedicine to prolong blood circulation time and improve drug efficacy. The conjugation of PEG to proteins, peptides, oligonucleotides (DNA, small interfering RNA (siRNA), microRNA (miRNA)) and nanoparticles is a well-established technique known as PEGylation, with PEGylated products have been using in clinics for the last few decades. However, it is increasingly recognized that treating patients with PEGylated drugs can lead to the formation of antibodies that specifically recognize and bind to PEG (i.e., anti-PEG antibodies). Anti-PEG antibodies are also found in patients who have never been treated with PEGylated drugs but have consumed products containing PEG. Consequently, treating patients who have acquired anti-PEG antibodies with PEGylated drugs results in accelerated blood clearance, low drug efficacy, hypersensitivity, and, in some cases, life-threatening side effects. In this succinct review, we collate recent literature to draw the attention of polymer chemists to the issue of PEG immunogenicity in drug delivery and bioconjugation, thereby highlighting the importance of developing alternative polymers to replace PEG. Several promising yet imperfect alternatives to PEG are also discussed. To achieve asatisfactory alternative, further joint efforts of polymer chemists and scientists in related fields are urgently needed to design, synthesize and evaluate new alternatives to PEG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Anti-PEG IgM production as a function of time interval was tested in sera of rats intravenously injected with PEGylated liposomal gambogenic acid (PEG-GEA-L) at 1.500 mg/kg (a) [57]. Mice were treated with PEGylated liposomes of 1 μmol/kg, and the production of anti-PEG IgM in mouse sera was determined as a function of time (b) [58]. The effect of PEG-GEA-L doses on anti-PEG IgM production was recorded on the fifth day after the first injection. Rats were treated with low (1.125 mg/kg), medium (1.500 mg/kg), and high (1.875 mg/kg) dosages. ELISA was utilized to determine anti-PEG IgM (c). Anti-PEG IgM in organ tissues of rats that were intravenously injected with various PEG-GEA-L doses (d). Used with permission from [57]. (* p < 0.05, ** p < 0.01).](https://figures.cochat.ai/paper-figures/7f992d6c8db34717873a1a30c4da9e3e/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-3.jpg)
![Figure 4 Production of anti-PEG IgM in the serum of mice injected PEGylated liposomes (PL) with various functional groups were determined by ELISA on the fifth day after administration. The lowest immunogenicity was exhibited by PL–OH (a). C3 binding in the serum of mice injected P–OCH3 and PL–OH on the fifth day, with non-treated mice as the control sample. Sera were diluted with a gelatin veronal buffer with Mg++ and Ca++ (GVB++) buffer (b) and an Mg2+/ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) buffer (c). Mice treated with PL–OH demonstrated the highest compliment activation, driving the ABC phenomenon (d). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [65]. Production of anti-PEG IgM rat sera against PEGylated emulsions (DE) with various functional groups seven days post-administration (e). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [66]. (* p < 0.05, ** p < 0.01, *** p < 0.001).](https://figures.cochat.ai/paper-figures/334fab17dd8d42068469652d228b7ccc/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-4.jpg)



![Figure 8 Chemical structure of the zwitterionic carboxybetaine functionalized polypeptide (PepCB) [79] (a). The preparation of poly(2-methacryloyloxyethyl phosphorylcholine)/poly(β-amino ester) (PMPC/PAE) mixed shell micelles (MSMs) with pH-sensitive behavior: MSMs were in zwitterionic state at a physiological blood pH (7.4) and in a cationic form within the tumor microenvironment (pH 6.5) (b).](https://figures.cochat.ai/paper-figures/52e563c21690478d8f338572002a504f/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these chemical modifications can potentially decrease transduction efficiency, lower production yield, alter biodistribution of AAV vectors, and result in anti-polymer antibody formation [198, 199].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · cited 3×
“However, the repeated administration of these polymers and/or NP-polymer conjugates may still trigger the production of anti-polymer antibodies, and further studies are needed to fully elucidate their immunogenic profiles [75,76].”
BackgroundPEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
Jiang, S., & Cao, Z. (2010) · Advanced Materials · doi:10.1002/adma.200901407 · Cited by 2,027 · cited 4×
“Synthetic zwitterionic materials such as poly(carboxybetaine) (pCB) and poly(sulfobetaine) (pSB) (Figure 7) have been proposed as PEG alternatives due to their strong hydration, conferring high resistance to nonspecific protein fouling in addition to their inherently low immunogenicity [77,78].”
BackgroundInfluentialChemistry for peptide and protein PEGylation
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00022-4 · Cited by 1,604
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708 · cited 3×
“When considering continuously increasing PEG density, it was shown that high PEG densities did not significantly impact NP clearance from circulation [59], though discussion of the relationship between clearance and anti-PEG IgM production, as a known causative factor of ABC, was omitted [37].”
Background
Research works printed but not linked: 4
- 23. Mukhopadhyay S. Nano drugs: A critical review of their patents and market. In: Mohapatra S.S., Ranjan S., Dasgupta N., Mishra R.K., Thomas S., editors. Characterization and Biology of Nanomaterials for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery. Elsevier Ltd.; Amsterdam, The Netherlands: 2019. pp. 523–551.
- 39. Elsadek N.E., Abu Lila A.S., Ishida T. 5-Immunological responses to PEGylated proteins: Anti-PEG antibodies. In: Pasut G., Zalipsky S., editors. Polymer-Protein Conjugates. Elsevier; Amsterdam, The Netherlands: 2020. pp. 103–123.
- 47. Seppälä J.T.S., Mäkelä O. Hapten. In: Roitt I., Delves P., editors. Encyclopedia of Immunology. 2nd ed. Elsevier Ltd.; Amsterdam, The Netherlands: 1998. pp. 1050–1052.
- 72. Abbina S., Parambath A. PEGylation and its alternatives: A summary. In: Parambath A., editor. Engineering of Biomaterials for Drug Delivery Systems: Beyond Polyethylene Glycol. Elsevier Ltd.; Amsterdam, The Netherlands: 2018. pp. 363–376.
Cited by
Items 301–400 of 669
Hydrophilic Random Cationic Copolymers as Polyplex-Formation Vectors for DNA
Chrysostomou, V., Katifelis, H., Gazouli, M., DIMAS, K. S., Demetzos, C., & Pispas, S. (2022) · Materials · doi:10.3390/ma15072650 · Cited by 20
“For instance, OEGMAs with short side chains (less than nine repeated units of ethylene glycol) present thermoresponsive behavior [20,22], while OEGMAs with long side chains provide increased solubility and enhanced stealth and shielding properties [23,24].”
BackgroundInvestigating the mechanism of action of DNA-loaded PEGylated lipid nanoparticles
Digiacomo, L., Renzi, S., Quagliarini, E., Pozzi, D., Amenitsch, H. W., Ferri, G., Pesce, L., Lorenzi, V. D., Matteoli, G., Cardarelli, F., et al. (2023) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2023.102697 · Cited by 16
“These could involve the employment of PEG alternatives, 41 or the design of artificial biomolecular coronas, 42 which could simultaneously enhance the targeting properties of NPs and prevent adverse immune reactions.”
Design and evaluation of curcumin-loaded poloxamer hydrogels as injectable depot formulations
Jose, A. D., Foo, K. L., Hu, G., Ngar, L., Ryda, B., Jaiswal, J. K., Wu, Z., Agarwal, P., & Thakur, S. S. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114372 · Cited by 17
Sarkar, K., Chatterjee, A., Bankura, B., Bank, S., Paul, N., Chatterjee, S., Das, A., Dutta, K., Chakraborty, S., De, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307166 · Cited by 18
Hassanel, D. N. B. P., Pilkington, E. H., Ju, Y., Kent, S. J., Pouton, C. W., & Truong, N. P. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124695 · Cited by 17
Self-citationTransforming cancer treatment: The potential of nanonutraceuticals
Kumar, G., Virmani, T., Chhabra, V., Virmani, R., Pathak, K., Akhtar, M. S., Asim, M. H., Arshad, S., Siddique, F., & Fonte, P. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124919 · Cited by 17
Comparing Zwitterionic and PEG Exteriors of Polyelectrolyte Complex Micelles
Ting, J., Marras, A. E., Mitchell, J. D., Campagna, T. R., & Tirrell, M. (2020) · Molecules · doi:10.3390/molecules25112553 · Cited by 18
Why nanodiamond carriers manage to overcome drug resistance in cancer
Benson, V., & Amini, A. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.52 · Cited by 22
Yoshinaga, N., Naito, M., Tachihara, Y., Boonstra, E., Osada, K., Cabral, H., & Uchida, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060800 · Cited by 17
“Moreover, the PEG strand can be replaced with alternatives, such as zwitterionic polymers [45].”
BackgroundAmina, M., Musayeib, N. M. A., Al-Hamoud, G. A., Al-Dbass, A. M., El-Ansary, A. K., & Ali, M. A. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.06.052 · Cited by 16
“PEG has been reported to serve as bioconjugate to various illness drugs by coupling itself with the target drug to improve the pharmacokinetic features of drug treatment (Hoang Thi et al., 2020).”
BackgroundOptimal delivery strategies for nanoparticle-mediated mRNA delivery
Li, X., Guo, X., Hu, M., Cai, R., & Chen, C. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02455a · Cited by 17
Gubarev, A. S., Lezov, A. A., Podseval’nikova, A. N., Mikusheva, N. G., Fetin, P. A., Zorin, I. M., Aseyev, V. O., Sedláček, O., Hoogenboom, R., & Tsvetkov, V. N. (2023) · Polymers · doi:10.3390/polym15030623 · Cited by 17
Silveira, M. J., Martins, C., Cruz, T., Castro, F., Costa, Â. M., Chester, K. A., Oliveira, M. J., & Sarmento, B. F. C. C. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02126-4 · Cited by 15
“…a PEG of 5 K was selected since this molecular weight has been associated with a prolonged blood circulation time due to lower absorption of serum proteins and interaction with macrophages reduced kidney’s clearance, therefore increasing the probability of a successful anti-tumor therapy [30, 31].”
BackgroundSmart polymeric nanostructures for targeted delivery of therapeutics
Dhara, M. (2020) · Journal of Macromolecular Science Part A · doi:10.1080/10601325.2020.1842766 · Cited by 16
Inhalable micro/nanoparticles for pulmonary delivery of macromolecular therapeutics: A review
Xie, S., Fatemipayam, N., Zhang, J., Aichele, C. P., & Ramsey, J. D. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123550 · Cited by 17
Ensminger, Y., Rashmi, R., Karimov, M., Nölte, G., Hafke, M., Schmitt, A., Díaz‐Oviedo, C. D., Köbberling, J., & Haag, R. (2025) · Macromolecular Rapid Communications · doi:10.1002/marc.202500428 · Cited by 20
Pritzlaff, A. M., Ferré, G., Dargassies, E., Williams, C. O., Gonzalez, D. D., & Eddy, M. T. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01522 · Cited by 15
Extended Intraocular Drug-Delivery Platforms for the Treatment of Retinal and Choroidal Diseases
Wykoff, C. C., Kuppermann, B. D., Regillo, C. D., CHANG, M. A., Hariprasad, S. M., Duker, J. S., Altaf, S. S., & Saïm, S. (2024) · Journal of VitreoRetinal Diseases · doi:10.1177/24741264241267065 · Cited by 16
Anaki, A., Tzror-Azankot, C., Motiei, M., Sadan, T., & Popovtzer, R. (2024) · Nanoscale Advances · doi:10.1039/d4na00134f · Cited by 15
Chemo-Enzymatic PEGylation/POxylation of Murine Interleukin-4
Haas, D., Hauptstein, N., Dirauf, M., Drießen, M. D., Ruopp, M., Schubert, U. S., Lühmann, T. C., & Meinel, L. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00495 · Cited by 16
Viana, D. B., Mathieu‐Gaedke, M., Leão, N. M., Böker, A., Soares, D. C. F., Glebe, U., & Tebaldi, M. L. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103995 · Cited by 17
Kehrein, J., & Sotriffer, C. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00636 · Cited by 14
Vaccine Development for Coronavirus (SARS-CoV2) Disease (Covid-19); Lipid Nanoparticles
Malabadi, R. B., Kolkar, K. P., Meti, N. T., & CHALANNAVAR, R. K. (2021) · International journal of research and scientific innovation · doi:10.51244/ijrsi.2021.8312 · Cited by 18
Hung, H., Kao, W.-C., Shen, C., Chang, K.-B., Tang, C., Yang, M., Yang, Y., Yeh, C.-A., Li, J.-J., & Hsieh, H.-H. (2021) · Cells · doi:10.3390/cells10112854 · Cited by 14
“The PEG antibodies may cause the failure of the clinical therapy [56,57].”
BackgroundRecent advancements in design of nucleic acid nanocarriers for controlled drug delivery
Mosley, R. J., Rucci, B., & Byrne, M. E. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02325c · Cited by 14
Macromolecular chemistry: An introduction
Selvaraj, C., Dinesh, D. C., Rajaram, K., Sundaresan, S., & Singh, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90995-2.00007-2 · Cited by 19
Designing biofunctional hydrogels for stem cell biology and regenerative medicine applications
Thi, T. T. H., Laney, M., Zhang, H., Martinez, F., Lee, Y., & Jang, Y. C. (2023) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2023.08.042 · Cited by 15
Self-Assembled Micelles of Amphiphilic PEGylated Drugs for Cancer Treatment
Amili, M. A., Zhu, J., Wang, Z., & Guo, S. (2021) · Current Drug Targets · doi:10.2174/1389450122666201231130702 · Cited by 15
PEGylated Nanoparticles as a Versatile Drug Delivery System
Mohapatra, P., Singh, D., & Sahoo, S. K. (2021) · Wiley eBooks · doi:10.1002/9783527832095.ch10 · Cited by 17
Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies
Gabel, M., Knauss, A., Fischer, D., Neurath, M. F., & Weigmann, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213929 · Cited by 14
“, poly (carboxybetaine), poly (sulfobetaine)) are currently under intensive investigation due to PEG side effects such as the ABC phenomenon [67], the formation of PEG antibodies, as well as a low drug efficacy as a consequence of anti-PEG antibodies [68,69].”
BackgroundSOCS1‐KIR Peptide in PEGDA Hydrogels Reduces Pro‐Inflammatory Macrophage Activation
Jha, A., Larkin, J., & Moore, E. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300237 · Cited by 13
Unagolla, J. M., Gaihre, B., & Jayasuriya, A. C. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300414 · Cited by 13
Eş, İ., Thakur, A., Khaneghah, A. M., Foged, C., & de la Torre, L. G. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108342 · Cited by 15
Effect of Poly(ethylene glycol) Configuration on Microbubble Pharmacokinetics
Navarro-Becerra, J. Á., Castillo, J. I., & Borden, M. A. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01764 · Cited by 16
Tumor versus Tumor Cell Targeting in Metal-Based Nanoparticles for Cancer Theranostics
Urbano‐Gámez, J. D., Guzzi, C., Bernal, M., Solivera, J., Martínez-Zubiaurre, I., Caro, C., & García‐Martín, M. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105213 · Cited by 14
“The reduction in opsonization not only decreases the potential inflammatory response derived from mNP injection but also increases its circulation time in the bloodstream [134].”
BackgroundJiang, Y., Jiang, B., Wang, Z., Li, Y., Cheung, J. C., Yin, B., & Wong, S. H. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168888 · Cited by 16
Cationized extracellular vesicles for gene delivery
Klyachko, N. L., Haney, M. J., Lopukhov, A. V., & Le‐Deygen, I. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-75985-y · Cited by 14
Premcheska, S., Skirtach, A. G., & Kaczmarek, A. M. (2025) · Advanced NanoBiomed Research · doi:10.1002/anbr.202500003 · Cited by 15
Dual-atom nanozymes: Synthesis, characterization, catalytic mechanism and biomedical applications
Bi, R., Liu, J. P., Cai, Y., Zhang, S., Lu, M., Du, C., Liu, M., Ding, X., Xiao, K., Li, S., et al. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114774 · Cited by 13
Allard, J. L., Shields, K. A., Munro, T. P., & Lua, L. H. L. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109996 · Cited by 14
Firouzabadi, K., Karimi, E., & Tabrizi, M. H. (2022) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2399 · Cited by 13
Design principles of bioinspired interfaces for biomedical applications in therapeutics and imaging
Shih, C.-P., Tang, X., Kuo, C. W., Chueh, D., & Chen, P. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.990171 · Cited by 18
The development of highly dense highly protected surfactant ionizable lipid RNA loaded nanoparticles
González-Rioja, R., Salazar, V. A., Bastús, N. G., & Puntes, V. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129296 · Cited by 14
Intrinsically Disordered Synthetic Polymers in Biomedical Applications
Yüce, E., Domb, A. J., Kasem, H., Uversky, V. N., & Coskuner‐Weber, O. (2023) · Polymers · doi:10.3390/polym15102406 · Cited by 13
“the immunogenicity of drugs, which can be particularly important for biologic drugs such as proteins [23,24].”
BackgroundPolymeric Nanoreactors as Emerging Nanoplatforms for Cancer Precise Nanomedicine
Li, X., Zhao, X., Lv, R., Hao, L., Huo, F., & Yao, X. (2021) · Macromolecular Bioscience · doi:10.1002/mabi.202000424 · Cited by 13
Ahmed, S., Mujahid, M. H., Kour, M., Fatima, S., Ahamad, S., Mishra, S. K., Bhat, A. R., Abu‐Rayyan, A., & Tebeje, B. A. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103459 · Cited by 14
Synthesis and photodynamic efficacy of water-soluble protoporphyrin IX homologue with mPEG550
Başoğlu, H., Değirmencioğlu, İ., & Eyüpoğlu, F. C. (2021) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2021.102615 · Cited by 12
Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics
Afrin, H., Salazar, C. J. J., Kazi, M., Ahamad, S. R., Alharbi, M., & Nurunnabi, M. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.01.011 · Cited by 13
Çalbaş, B., Keobounnam, A. N., Korban, C., Doratan, A. J., Jean, T., Sharma, A. Y., & Wright, T. A. (2024) · Biomaterials Science · doi:10.1039/d3bm01861j · Cited by 15
Hamed, R., Obeid, R. Z., Abu‐Huwaij, R., Qattan, D., & Shahin, N. A. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01642-6 · Cited by 13
“In addition, PEGylation prolongs the circulation time of nanoparticles and improves their specific cell targeting [34 ].”
Robinson, K. J., Voelcker, N. H., & Thissen, H. W. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.12.037 · Cited by 18
Uchôa, A. F. C., Formiga, A. L. D., Cardoso, A. L., Pereira, G. M. A., Carvalho, L. M. M., de Souza, P. H. O., Silva, A. L. E., de Souza, R. R. M., Sobral, M. V., da Silva, M. S., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030363 · Cited by 12
“Finally, PEG, a widely Finally, PEG, a widely used polymer in nanomedicine, can prolong circulation time and improve drug efficacy [41]. improve drug e ffi cacy [41].”
Dehghan, F., Gholipour‐Kanani, A., Dolatabadi, M. K., & Bahrami, S. H. (2022) · Journal of Applied Polymer Science · doi:10.1002/app.52463 · Cited by 12
Miranda, M. S., Almeida, A. F., Gomes, M. E., & Rodrigues, M. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911793 · Cited by 12
“PEG is a highly versatile polymer with excellent solubility in aqueous media and chemical labiality for chemical modification with different functional groups [5].”
BackgroundPerecin, C. J., Sponchioni, M., Auriemma, R., Cerize, N. N. P., Moscatelli, D., & Varanda, L. C. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c03712 · Cited by 15
Ha, N. G., Kim, S. L., Lee, S. H., & Lee, W. J. (2023) · Skin Research and Technology · doi:10.1111/srt.13499 · Cited by 14
Guo, Z., Zhang, S., Yue, L., Zhang, H., Qian, X., Qian, S., & Sheng, K. (2021) · Journal of Polymers and the Environment · doi:10.1007/s10924-021-02267-3 · Cited by 12
Ahmed, Y. W., Tsai, H., Wu, T.-Y., Darge, H. F., & Chen, Y.-S. (2023) · Materials Advances · doi:10.1039/d3ma00341h · Cited by 12
PEtOxylated polyesteramide nanoparticles for the delivery of anti-inflammatory drugs
Behnke, M., Vollrath, A., Dahlke, P., Páez-Larios, F., Chi, M., Tsarenko, E., Jordan, P. M., Weber, C., Dirauf, M., Czaplewska, J. A., et al. (2023) · Materials Today Chemistry · doi:10.1016/j.mtchem.2023.101848 · Cited by 11
Razavi, M. S., Ahmadi, F., Ebrahimnejad, P., Akbarzadeh, A., Farokhrou, M., & Nokhodchi, A. (2024) · Pharmaceutical Sciences · doi:10.34172/ps.2023.27 · Cited by 17
Exemplifying interspecies variation of liposome in vivo fate by the effects of anti-PEG antibodies
Wu, E., Guan, J., Yu, Y., Lin, S., Ding, T., Chu, Y., Pan, F., Liu, M., Yang, Y., Zhang, Z., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.07.009 · Cited by 12
Recent Advances in Polymer Shell Oily-Core Nanocapsules for Drug-Delivery Applications
AbdElhamid, A. S., Zayed, D. G., Heikal, L., Khattab, S. N., Mady, O. Y., El‐Gizawy, S. A., & Elzoghby, A. O. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0037 · Cited by 12
Itzhaki, E., Elias, Y., Moskovits, N. B.-C., Stemmer, S. M., & Margel, S. (2023) · Journal of Functional Biomaterials · doi:10.3390/jfb14040215 · Cited by 12
“The latter is critical for prevention of dye/drug leakage [48,49].”
BackgroundRecent advances in drug delivery systems based on natural and synthetic polymes for treating obesity
Xiao, M., Wang, Z., Li, C., Zhang, K., Hou, Z., Sun, S., & Yang, L. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129311 · Cited by 11
Linear Polyglycerol for N-terminal-selective Modification of Interleukin-4
Tully, M., Hauptstein, N., Licha, K., Meinel, L., Lühmann, T. C., & Haag, R. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.10.032 · Cited by 12
ToF-SIMS evaluation of PEG-related mass peaks and applications in PEG detection in cosmetic products
Shen, Y., Son, J., & Yu, X.-Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-65504-4 · Cited by 11
Humphries, J., Fletcher, N. L., Sonderegger, S., Bell, C. A., Kempe, K., & Thurecht, K. J. (2024) · ACS Nano · doi:10.1021/acsnano.4c07317 · Cited by 17
Poly(2‐Hydroxymethyl‐2‐Oxazoline) as Super‐Hydrophilic Antifouling Polymer
Jana, S., Roels, M., Leiske, M. N., Bernhard, Y., Geest, B. G. D., Hecke, K. V., & Hoogenboom, R. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202424873 · Cited by 12
Tomoaia-Cotişel, M., Kun, A.-Z., Rácz, C.-P., Tomoaia, G., Mocanu, A., Forizs, E., Avram, A., Rácz, L.-Z., Pop, L., Sárközi, M., et al. (2025) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-025-14111-0 · Cited by 10
Pareek, A., Alaseem, A. M., Alasiri, G. A., Kapoor, D. U., & Prajapati, B. G. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126169 · Cited by 10
Hadad, E., Rudnick‐Glick, S., Itzhaki, E., Avivi, M. Y., Grinberg, I., Elias, Y., & Margel, S. (2020) · Polymers · doi:10.3390/polym12122996 · Cited by 10
“Previous studies showed that PEGylated drugs reduce penetration rates into cells [36] and induce formation of antibodies [38].”
BackgroundMethodSincari, V., Petrova, S. L., Konefał, R., Hrubý, M., & Jäger, E. (2021) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2021.104875 · Cited by 10
Synthesis and Study of Thermoresponsive Amphiphilic Copolymers via RAFT Polymerization
Kavaliauskaite, M., Steponavičiūtė, M., Kievisaite, J., Katelnikovas, A., & Klimkevičius, V. (2022) · Polymers · doi:10.3390/polym14020229 · Cited by 10
“First, the PEGs are known as bio-inert materials that could hide from the immune system and could avoid opsonization in blood [43].”
BackgroundPipertzis, A., Kafetzi, M., Giaouzi, D., Pispas, S., & Floudas, G. A. (2022) · ACS Applied Polymer Materials · doi:10.1021/acsapm.2c00987 · Cited by 10
Wang, Y., Kim, M., Buckley, C., Maynard, H. D., Langley, R. J., & Perry, J. K. (2023) · Protein Science · doi:10.1002/pro.4727 · Cited by 10
“For example, the use of degradable polymers may avoid common issues associated with PEG such as production of anti-PEG antibodies, and potential accumulation in tissues with longterm treatment (Hoang Thi et al., 2020; Ibrahim et al., 2022; Zhang et al., 2016).”
BackgroundMaurelli, A. M., Leo, V. D., Daniello, V., Calvano, C. D., Ciriaco, F., Milano, F., Ingrosso, C., Cataldi, T. R. I., Gioia, S. D., Conese, M., et al. (2024) · Materials Today Chemistry · doi:10.1016/j.mtchem.2024.101994 · Cited by 11
Zhao, M., Guo, X., Su, C., Li, M. C., Wang, X., Pan, D., Wang, L., Xu, Y., Chen, C., Yang, M., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202400960 · Cited by 10
Ebrahimnia, M., Alavi, S., Vaezi, H., Karamat-Iradmousa, M., & Haeri, A. (2024) · EXCLI journal · doi:10.17179/excli2023-6747 · Cited by 18
Liu, S., Wang, L., Zhao, B., Wang, Z., Wang, Y., Sun, B., & Liu, Y. (2020) · RSC Advances · doi:10.1039/d0ra03069d · Cited by 10
Malinga, T. W., Kudanga, T., & Mbatha, L. S. (2021) · Advances in Natural Sciences Nanoscience and Nanotechnology · doi:10.1088/2043-6262/ac389c · Cited by 10
Bardoula, V., Leclercq, L., Hoogenboom, R., & Nardello‐Rataj, V. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.11.018 · Cited by 10
Dong, P., Liu, J., Lv, H., Wu, J., Zhang, N., Wang, S., Li, X., Hu, J., Wang, A., Li, D. J., et al. (2022) · Biomaterials Science · doi:10.1039/d2bm00337f · Cited by 10
Recombinant manufacturing of multispecies biolubricantsPreprint
Colville, M. J., Huang, L., Schmidt, S., Chen, K., Vishwanath, K., Su, J., Williams, R. M., Bonassar, L. J., Reesink, H. L., & Paszek, M. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.05.592580 · Cited by 12
“29,30 CMP-Neu5Ac hydroxylase activity in CHO cells allows for the glycosylation of proteins with Neu5Gc sialic acids, which are not synthesized in humans and can provoke antibody responses.”
Yu, C.-C., Su, Y., & Yeh, Y. (2024) · European Polymer Journal · doi:10.1016/j.eurpolymj.2024.113469 · Cited by 9
Fluorescent Poly(ε-Caprolactone)s Micelles for Anticancer Drug Delivery and Bioimaging
Babanyinah, G. K., Bhadran, A., Polara, H., Shah, T. V., Biewer, M. C., & Stefan, M. C. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c00262 · Cited by 9
Humphries, J., Warne, N. M., Feeney, O. M., Thurecht, K. J., & Kempe, K. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114838 · Cited by 11
Mohammadian, S., Khazaei, M., Maghami, P., Avan, A., & Rezaei, M. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230210140212 · Cited by 10
Raina, N., Singh, E., Ahanger, I. A., Shahid, M., Israil, Hassan, M. I., Ahmad, F., Singh, A. K., & Islam, A. (2023) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2023.121909 · Cited by 9
Toncheva-Moncheva, N., Dimitrov, E., Grancharov, G., Momekova, D. B., Petrov, P. D., & Rangelov, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082128 · Cited by 10
Structural optimization and prospect of constructing hemoglobin oxygen carriers based on hemoglobin
Ma, Y., Zhang, Q., Dai, Z., Li, J., Li, W., Fu, C., Wang, Q., & Yin, W. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19430 · Cited by 9
Khan, D., Ahmed, N., Qindeel, M., Mir, M., Ullah, N., & Rehman, A. U. (2024) · BioNanoScience · doi:10.1007/s12668-024-01600-z · Cited by 10
“PCLs are exploited with the help of nanotechnology in targeted drug delivery systems, including those for the delivery of macromolecular proteins, peptides, monoclonal antibodies, vaccines, and other medical devices and tissue engineering [16–18].”
Sukumar, U. K., Telichko, A. V., Wang, H., Hyun, D., Johnson, E. G., Kent, M. S., Rebhun, R. B., Dahl, J., Culp, W. T. N., & Paulmurugan, R. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000120 · Cited by 9
Bhattacharjee, S. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00940 · Cited by 9
Random cationic copolymers as nanocarriers for ovalbumin
Vardaxi, A., & Pispas, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104177 · Cited by 9
Rheinberger, T., Wolf, T., & Wurm, F. R. (2020) · European Polymer Journal · doi:10.1016/j.eurpolymj.2020.109700 · Cited by 10
Hadad, E., Rudnick‐Glick, S., Grinberg, I., Yehuda, R., & Margel, S. (2020) · RSC Advances · doi:10.1039/d0ra06069k · Cited by 9
Potential nanotechnology-based diagnostic and therapeutic approaches for Meniere's disease
Kashizadeh, A., Pastras, C. J., Rabiee, N., Mohseni‐Dargah, M., Mukherjee, P., & Asadnia, M. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102599 · Cited by 9
Benznidazole-Loaded Polymeric Nanoparticles for Oral Chemotherapeutic Treatment of Chagas Disease
Sousa, L. R. D., Duarte, T. H. C., Xavier, V. F., das Mercês, A. C., Vieira, G. M., Martins, M. D., Carneiro, C. M., dos Santos, V. M. R., dos Santos, O. D. H., & Vieira, P. M. D. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060800 · Cited by 8
“It has excellent characteristics, including water solubility, biocompatibility, and good tolerance [21, 23,24].”
BackgroundElter, J. K., Sedlák, F., Palušák, T., Bernardová, N., Lobaz, V., Tihlaříková, E., Neděla, V., Šácha, P., & Hrubý, M. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.4c01052 · Cited by 8
Gibson, J., Dhungana, A., Pokhrel, M., Arthur, B., Suresh, P., Adebayo, O., & Cottle, R. N. (2025) · Cells · doi:10.3390/cells14100711 · Cited by 10
“This is, of course, combined with the fact that ex vivo electroporation does not raise concerns associated with added immunogenicity or insertional mutagenesis and subsequent HCC as commonly observed with various in vivo approaches, such as AAVs and lipid nanoparticles [18–21 , 42–”
Metadata
- Authors
- Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P.
- Affiliations
- Biomaterials and Nanotechnology Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 758307, Vietnam
- Monash University (AU)
- Graduate University of Science and Technology (VN)
- Yale University (US)
- Ajou University (KR)
- Corresponding author
- Truong, Nghia P.
- ORCID
- Venue
- Polymers
- Publisher
- MDPI AG
- Published
- 2020-02-02
- Volume
- 12
- Issue
- 2
- Pages
- 298
- ISSN
- 2073-4360 (ISSN-L)
- PMC
- PMC7077443
- OpenAlex
- W3003603323
- Cited by
- 668
- References
- 79
- Citations by year
- 2026: 63 · 2025: 106 · 2024: 117 · 2023: 126 · 2022: 118 · 2021: 85 · 2020: 53
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Polymers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Australian Research Council (DE180100076, DP200100231)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- polyethylene glycol, anti-PEG antibodies, PEGylation, PEG alternatives, drug delivery, bioconjugation, nanomedicine, blood circulation time, hypersensitivity, siRNA, microRNA, oligonucleotides, nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.